Guadecitabine is used to treat certain types of blood cancers, particularly myelodysplastic syndromes (a condition where bone marrow doesn't make enough healthy blood cells). It works by helping to reactivate genes that have been turned off in cancer cells.[1] AstPlayer is currently being investigated across 7 indications[3], with its most advanced program in Phase 2.[1]
AstPlayer is one of 160 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
199 competitors in Lung Cancer
Keytruda
Imfinzi
Opdivo
Beyfortus
Abraxane
Tecentriq
Alunbrig
DATROWAY
Ilaris
Tarlatamab-Dznl
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details